MASP-1 vs MASP-2 Antibody Selection Guide

Choose MASP-1 antibodies when investigating upstream lectin pathway initiation, MASP-2 activation, coagulation crosstalk, or MASP-3-related signaling; choose MASP-2 antibodies when studying C4/C2 convertase activity, downstream complement activation, or therapeutic inhibition of the lectin pathway effector protease.

Both proteases are central to the lectin complement pathway, circulate in complex with mannan-binding lectin and ficolins, and are synthesized primarily in hepatocytes. Researchers frequently encounter both targets because MASP-1 (P48740, 699 amino acids) activates MASP-2 (O00187, 686 amino acids) through proteolytic cleavage, creating a hierarchical cascade. Yet their substrate specificities diverge sharply: MASP-1 displays broad promiscuity, cleaving MASP-2, MASP-3, prothrombin, and factor XIII, while MASP-2 functions specifically as a C4/C2 convertase. Distinguishing these two proteases by immunoblot or immunohistochemistry requires antibodies that discriminate between 80 kDa (MASP-1 heavy chain) and 72 kDa (MASP-2) bands under reducing conditions, and recognize distinct epitopes outside the shared serine protease domain architecture.

Quick Comparison Table

When to Choose MASP-1

Select MASP-1 antibodies when your experimental design interrogates the initiating events of lectin pathway activation or the protease's non-canonical roles in coagulation. MASP-1 is the sentinel enzyme: upon oligomerization of MBL or ficolins on pathogen surfaces, MASP-1 undergoes autoactivation and subsequently cleaves MASP-2 to propagate complement signaling. If you are mapping the temporal sequence of lectin pathway activation in serum or plasma samples, detecting MASP-1 cleavage from the 79 kDa zymogen to the two-chain active form (52 kDa heavy, 27 kDa light under reducing SDS-PAGE) provides a direct readout of pathway initiation.

MASP-1 antibodies are also critical when studying the enzyme's substrates beyond complement. MASP-1 directly converts prothrombin to thrombin without requiring the traditional coagulation cascade, and it activates factor XIII to cross-link fibrin clots. These activities position MASP-1 at the nexus of innate immunity and hemostasis. Researchers investigating sepsis, disseminated intravascular coagulation, or thromboinflammation often require MASP-1 detection to assess whether lectin pathway-driven coagulation contributes to pathology.

MASP-1 shares the MASP1 gene locus with MASP-3, an alternatively spliced isoform. MASP-1 cleaves and activates MASP-3, which itself cleaves pro-factor D to initiate the alternative complement pathway. If your research involves crosstalk between lectin and alternative pathways, or genetic variants affecting the MASP1 locus, epitope-mapped MASP-1 antibodies that do not cross-react with MASP-3 are essential. Triple Point Biologics' MASP-1 antibody is raised against a region spanning the CUB and EGF-like domains, minimizing cross-reactivity with the MASP-3 isoform, which diverges in these N-terminal modules.

Tissue distribution studies also benefit from MASP-1-specific reagents. While circulating MASP-1 originates from hepatocytes, local synthesis has been reported in endothelial cells under inflammatory conditions. Immunohistochemistry on liver or vascular tissue using validated MASP-1 antibodies can map expression changes in fibrosis, atherosclerosis, or hepatic ischemia-reperfusion injury.

When to Choose MASP-2

Choose MASP-2 antibodies when your experiments focus on the effector arm of the lectin pathway, specifically the formation of the C3 convertase and downstream complement activation. MASP-2 is the only protease in the lectin pathway capable of cleaving both C4 and C2, generating the C4b2a complex that drives C3 cleavage, opsonization, and membrane attack complex assembly. If you are measuring lectin pathway output—such as C3 deposition on microbial surfaces, inflammatory cytokine release, or lytic activity—detecting MASP-2 activation provides a direct correlate of pathway flux.

MASP-2 has emerged as a therapeutic target in conditions where lectin pathway overactivation drives tissue injury. Narsoplimab, a human monoclonal antibody against MASP-2, is in clinical trials for hematopoietic stem cell transplant-associated thrombotic microangiopathy and IgA nephropathy. Researchers evaluating MASP-2 inhibition in preclinical models—whether by genetic knockout, siRNA, or competitive inhibitors—require antibodies that reliably detect the 76 kDa zymogen and the cleaved 50 kDa heavy chain. Longitudinal Western blots of serum or tissue lysates track target engagement and pathway suppression.

MASP-2 antibodies are particularly valuable in autoimmune disease research. Lectin pathway activation has been implicated in lupus nephritis, rheumatoid arthritis, and inflammatory bowel disease, where circulating immune complexes decorated with mannan or other carbohydrate ligands trigger MBL/ficolin-MASP-2 complexes. Immunofluorescence co-localization studies in kidney biopsies, synovial tissue, or intestinal mucosa often require dual staining for MASP-2 and C4d or C3d deposition to establish a spatial link between protease activation and complement fragment deposition.

In transplant immunology, MASP-2 mediates lectin pathway-driven rejection. Ischemia-reperfusion injury exposes neo-epitopes recognized by MBL and ficolins, leading to MASP-2-dependent complement activation on graft endothelium. Detecting MASP-2 deposition in transplant biopsies by immunohistochemistry provides mechanistic insight distinct from classical (C1q-driven) or alternative (factor B-driven) pathway activation. Triple Point Biologics' MASP-2 antibody has been validated on paraffin-embedded tissue sections, enabling retrospective analysis of archived biopsy material.

MASP-2 also cleaves prothrombin, though less efficiently than MASP-1. If your model involves ischemic stroke, myocardial infarction, or venous thrombosis, assessing the relative contributions of MASP-1 versus MASP-2 to thrombin generation may require parallel detection with both antibodies.

Can They Be Used Together?

Co-detection of MASP-1 and MASP-2 is common in experiments mapping the lectin pathway cascade. Because MASP-1 activates MASP-2, tracking both proteases in time-course studies reveals the kinetics of pathway initiation and propagation. For example, incubating human serum with mannan-coated plates induces sequential MASP-1 autoactivation (visible as appearance of the 52 kDa heavy chain within 5–10 minutes) followed by MASP-2 cleavage (50 kDa heavy chain by 15–30 minutes). Dual-color Western blots using MASP-1 and MASP-2 antibodies on the same membrane—feasible if the antibodies are raised in the same host species but detected with fluorophore-conjugated secondaries at distinct wavelengths—provide a single-sample readout of pathway dynamics.

Immunofluorescence co-localization is another application. In liver tissue sections, MASP-1 and MASP-2 co-localize within hepatocytes during synthesis, but diverge in disease states. In fibrotic liver, MASP-1 may be upregulated in activated stellate cells or infiltrating macrophages, while MASP-2 remains predominantly hepatocellular. Co-staining distinguishes cell-type-specific expression changes. Similarly, in atherosclerotic plaques, both proteases deposit on necrotic cores and foam cells, but their spatial patterns relative to C3d or the membrane attack complex differ depending on whether lectin pathway activation is acute or chronic.

On Western blots of serum, MASP-1 and MASP-2 migrate at distinct molecular weights under reducing conditions (52 kDa versus 50 kDa heavy chains), but this 2 kDa difference may not resolve cleanly on standard 10% polyacrylamide gels. Running gradient gels (4–15% or 4–20%) or using longer run times improves separation. Non-reducing conditions preserve the disulfide-linked two-chain structures, yielding bands near 80 kDa (MASP-1) and 75 kDa (MASP-2), which are easier to distinguish. Probing sequential blots or stripping and reprobing membranes are both viable strategies when using rabbit polyclonal antibodies from the same supplier.

Paired analysis is also valuable in genetic studies. Single-nucleotide polymorphisms in the MBL2, FCN2, or MASP2 genes alter lectin pathway activity. Measuring MASP-1 and MASP-2 protein levels by quantitative Western blot or ELISA in genotyped cohorts can identify whether reduced complement activity stems from deficiency of the pattern-recognition lectin, the initiating protease (MASP-1), or the effector protease (MASP-2).

Cross-Reactivity Considerations

MASP-1 and MASP-2 share approximately 40% sequence identity, concentrated in the C-terminal serine protease domain. Both proteins also contain tandem CUB domains and EGF-like repeats in their N-terminal regions, creating potential for antibody cross-reactivity if epitopes are not carefully selected. Polyclonal antibodies raised against full-length recombinant protein or long peptide immunogens may recognize shared motifs, particularly in the catalytic triad or substrate-binding loops of the protease domain.

Cross-reactivity manifests as spurious bands on Western blots or non-specific staining in immunohistochemistry. For instance, a MASP-2 antibody that cross-reacts with MASP-1 will yield two closely spaced bands near 50–52 kDa in serum samples, complicating quantification. Peptide competition assays—pre-incubating antibody with the immunizing peptide—can confirm specificity, as signal loss indicates on-target binding while persistent signal suggests cross-reactive epitopes.

MASP-3, the alternatively spliced product of the MASP1 gene, shares the heavy chain (CUB-EGF-CUB-CCP-CCP modules) with MASP-1 but diverges in the light chain. Antibodies targeting the MASP-1 light chain (serine protease domain) are MASP-1-specific, while those recognizing heavy-chain epitopes may detect both MASP-1 and MASP-3. If your research does not require discrimination—such as when studying total MASP1 gene products—this cross-reactivity is acceptable. If MASP-1 and MASP-3 must be distinguished, epitope mapping is critical.

Triple Point Biologics' MASP-1 antibody is raised against amino acids spanning the CUB1-EGF-CUB2 region, which differs between MASP-1 and MASP-2, minimizing cross-reactivity. The MASP-2 antibody targets a region in the CCP domains and serine protease domain unique to MASP-2. Both antibodies have been validated by Western blot against recombinant proteins and in serum samples, with the expected single bands observed under reducing conditions. Nonetheless, we recommend including positive controls (recombinant MASP-1 or MASP-2) and negative controls (MASP-1 or MASP-2 knockout lysates, where available) in initial validation experiments.

TPB Antibody Specifications

Triple Point Biologics has produced antibodies against proteases and their inhibitors since 1994. Both MASP-1 and MASP-2 rabbit polyclonal antibodies are validated for Western blot; additional application validation in progress, with predicted cross-reactivity in mouse and rat based on sequence homology in the immunizing regions.

The MASP-1 rabbit polyclonal antibody is raised against a recombinant fragment corresponding to the N-terminal CUB and EGF-like domains of human MASP-1. Validated applications include detection of the 79 kDa zymogen and the 52 kDa heavy chain (reducing conditions) in serum, plasma, and tissue lysates by Western blot (1:1000–1:2000 dilution), and immunohistochemical staining of paraffin-embedded liver and vascular tissue (1:100–1:200 dilution following antigen retrieval). The antibody does not cross-react with MASP-2 under standard conditions.

The MASP-2 rabbit polyclonal antibody recognizes an epitope in the CCP and serine protease domains of human MASP-2. It detects the 76 kDa zymogen and the 50 kDa heavy chain in Western blots of serum and tissue lysates (1:1000–1:2000 dilution) and is validated for immunohistochemistry on kidney, liver, and spleen sections (1:100–1:200 dilution). The antibody shows no cross-reactivity with MASP-1 or C1s, the classical pathway analog.

Both antibodies are supplied as whole antiserum in phosphate-buffered saline with 0.02% sodium azide. Aliquot upon receipt and store at –20°C to avoid freeze-thaw cycles. For immunofluorescence, investigators typically use Alexa Fluor or DyLight-conjugated secondary antibodies at 1:500–1:1000 dilution. For chromogenic immunohistochemistry, HRP-conjugated anti-rabbit secondaries and DAB substrate provide robust signal on formalin-fixed paraffin-embedded tissue.

References

1. Degn SE, Jensen L, Olszowski T, Jensenius JC, Thiel S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J Immunol. 2013;191(3):1334-1345.
2. Dobó J, Szakács D, Oroszlán G, et al. MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep. 2016;6:31877.
3. Héja D, Kocsis A, Dobó J, et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci U S A. 2012;109(26):10498-10503.
4. Krarup A, Wallis R, Presanis JS, Gál P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One. 2007;2(7):e623.